Otis W. Brawley
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Otis W. Brawley has a total of 104 co-authors. Here are the top co-authors by number of shared publications:
- Channing Judith Paller
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD
3 shared publications Ahmedin Jemal
Surveilliance, Prevention, and Health Services Research American Cancer Society Atlanta Georgia USA
2 shared publicationsChanning J. Paller
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland
2 shared publications- Lin Wang
Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland
2 shared publications Richard C. Wender
Chief Cancer Control Officer, American Cancer Society, Atlanta, GA
2 shared publicationsRohan Ramalingam
Department of Oncology Johns Hopkins School of Medicine Baltimore MD USA
2 shared publications
Latest Publications
- 6 March 2026
- Published by ResearchHub Technologies, Inc.
usa american airlines customer service
- 19 February 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- p. OP2500688
Comparison of Characteristics and Outcomes of Patients With Metastatic Prostate Cancer With and Without Next-Generation Sequencing Testing
PURPOSE: Next-generation sequencing (NGS) is recommended for patients with metastatic prostate cancer (PC). Nationwide, testing rates are low. Whether PC disease characteristics and courses differ between those with and without NGS testing is unknown. We identified predictors of testing, explored likely reasons for lack of testing, and compared survival between those with and without testing. METHODS: We retrospectively reviewed patients with metastatic PC initially seen between 2020 and 2022 at Johns Hopkins. Clinical data and reasons for nontesting were abstracted from the electronic medical record. We conducted a logistic regression assessing predictors of NGS testing, adjusting for age, Gleason grade, marital status, and metastatic diagnosis year. We used Cox regression to compare overall survival, defined from the time patients had both a metastatic diagnosis and a visit at our institution until death/last follow-up, between those tested and not tested. We adjusted for age, Gleason grade, initial metastasis (M) stage, comorbidities, and time from metastatic diagnosis to first visit. RESULTS: Of the 435 patients, 257 (59%) had NGS testing. Older patients were less likely to have testing (adjusted odds ratio [aOR], 0.96 [95% CI, 0.94 to 0.98]). Unmarried patients were less likely to have testing (aOR, 0.62 [95% CI, 0.38 to 1.01]). Patients with Gleason Grade Group 5 were more likely to undergo testing than patients with Groups 1-3 (aOR, 1.86 [95% CI, 1.14 to 3.04]). Among those without testing, 139 (78%) had at least one potential reason for lack of testing in the medical record. The most common reason for nontesting was patient/disease factors (37%). CONCLUSION: Older and unmarried men with metastatic PC were less likely to obtain NGS testing, whereas those with high Gleason grade were more likely. Interventions are needed to improve testing rates.
- 19 February 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- p. OP2500688
Comparison of Characteristics and Outcomes of Patients With Metastatic Prostate Cancer With and Without Next-Generation Sequencing Testing
PURPOSE: Next-generation sequencing (NGS) is recommended for patients with metastatic prostate cancer (PC). Nationwide, testing rates are low. Whether PC disease characteristics and courses differ between those with and without NGS testing is unknown. We identified predictors of testing, explored likely reasons for lack of testing, and compared survival between those with and without testing. METHODS: We retrospectively reviewed patients with metastatic PC initially seen between 2020 and 2022 at Johns Hopkins. Clinical data and reasons for nontesting were abstracted from the electronic medical record. We conducted a logistic regression assessing predictors of NGS testing, adjusting for age, Gleason grade, marital status, and metastatic diagnosis year. We used Cox regression to compare overall survival, defined from the time patients had both a metastatic diagnosis and a visit at our institution until death/last follow-up, between those tested and not tested. We adjusted for age, Gleason grade, initial metastasis (M) stage, comorbidities, and time from metastatic diagnosis to first visit. RESULTS: Of the 435 patients, 257 (59%) had NGS testing. Older patients were less likely to have testing (adjusted odds ratio [aOR], 0.96 [95% CI, 0.94 to 0.98]). Unmarried patients were less likely to have testing (aOR, 0.62 [95% CI, 0.38 to 1.01]). Patients with Gleason Grade Group 5 were more likely to undergo testing than patients with Groups 1-3 (aOR, 1.86 [95% CI, 1.14 to 3.04]). Among those without testing, 139 (78%) had at least one potential reason for lack of testing in the medical record. The most common reason for nontesting was patient/disease factors (37%). CONCLUSION: Older and unmarried men with metastatic PC were less likely to obtain NGS testing, whereas those with high Gleason grade were more likely. Interventions are needed to improve testing rates.
- Top Cited PapersOpen Access
- 16 December 2025
- Published by Wiley in CA: A Cancer Journal for Clinicians
- Vol. 76 (1) , e70045
American Cancer Society’s Report on the Status of Cancer Disparities in the United States, 2025
Since 2021, the American Cancer Society has published its biennial report on the status of cancer disparities in the United States. In this 2025 report, the authors provide updated data on disparities in cancer occurrence and outcomes by sex, race, ethnicity, socioeconomic status (SES [educational attainment as a proxy]), and geographic location (including urbanicity of county of residence and congressional district), along with contributors to these disparities, including major cancer risk factors, screening, and select social determinants of health (SDOH) and health‐related social needs. The authors found substantial disparities across the cancer continuum, including risk factors, incidence, stage at diagnosis, receipt of care, survival, and mortality for many cancers and in evaluated SDOH by race and ethnicity, educational attainment, and geographic location. During 2019 through 2023, Black and American Indian/Alaska Native populations had the highest cancer mortality rates, both overall and for the leading causes of cancer death. Cancer mortality rates were also consistently higher among adults with lower SES. However, differences in cancer mortality were substantially larger by education than by race, indicating that SES plays a major role in driving racial disparities in cancer mortality. Overall cancer mortality rates were higher in Black adults than in White adults with the same education level by 7%–28% among males and by 2%–43% among females. Within each race, however, overall cancer mortality rates were higher in adults with ≤12 years of education than in those with ≥16 years of education by 143%–192% among males and by 71%–140% among females. Mortality from all cancers combined was 21% higher in nonmetropolitan than in large metropolitan counties, with the greatest differences for lung (45%) and cervical (36%) cancers and the smallest for prostate, female breast, and pancreatic cancers (7%–8%). By congressional district, the highest cancer mortality rates both overall and for lung, colorectal, and breast cancers were largely found in the South and East North‐Central division of the Midwest; however, for prostate cancer, there was no distinct geographic pattern. Sociodemographic groups that had higher cancer mortality generally had higher exposure to risk factors, lower health insurance coverage, and limited access to cancer prevention, early detection, and treatment compared with groups that had lower cancer mortality, largely reflecting fundamental disparities in SDOH. Mitigating cancer disparities in the United States requires intersectoral stakeholder engagement, targeted funding, effective policies at the federal, state, and local levels, and broad implementation of evidence‐based interventions, such as expanding health insurance coverage, including through strengthening Marketplaces and protecting and expanding access to Medicaid.
- 16 December 2025
- Published by Wiley in CA: A Cancer Journal for Clinicians
- Vol. 76 (1) , e70045
Top Cited PapersOpen AccessAmerican Cancer Society’s Report on the Status of Cancer Disparities in the United States, 2025
Since 2021, the American Cancer Society has published its biennial report on the status of cancer disparities in the United States. In this 2025 report, the authors provide updated data on disparities in cancer occurrence and outcomes by sex, race, ethnicity, socioeconomic status (SES [educational attainment as a proxy]), and geographic location (including urbanicity of county of residence and congressional district), along with contributors to these disparities, including major cancer risk factors, screening, and select social determinants of health (SDOH) and health‐related social needs. The authors found substantial disparities across the cancer continuum, including risk factors, incidence, stage at diagnosis, receipt of care, survival, and mortality for many cancers and in evaluated SDOH by race and ethnicity, educational attainment, and geographic location. During 2019 through 2023, Black and American Indian/Alaska Native populations had the highest cancer mortality rates, both overall and for the leading causes of cancer death. Cancer mortality rates were also consistently higher among adults with lower SES. However, differences in cancer mortality were substantially larger by education than by race, indicating that SES plays a major role in driving racial disparities in cancer mortality. Overall cancer mortality rates were higher in Black adults than in White adults with the same education level by 7%–28% among males and by 2%–43% among females. Within each race, however, overall cancer mortality rates were higher in adults with ≤12 years of education than in those with ≥16 years of education by 143%–192% among males and by 71%–140% among females. Mortality from all cancers combined was 21% higher in nonmetropolitan than in large metropolitan counties, with the greatest differences for lung (45%) and cervical (36%) cancers and the smallest for prostate, female breast, and pancreatic cancers (7%–8%). By congressional district, the highest cancer mortality rates both overall and for lung, colorectal, and breast cancers were largely found in the South and East North‐Central division of the Midwest; however, for prostate cancer, there was no distinct geographic pattern. Sociodemographic groups that had higher cancer mortality generally had higher exposure to risk factors, lower health insurance coverage, and limited access to cancer prevention, early detection, and treatment compared with groups that had lower cancer mortality, largely reflecting fundamental disparities in SDOH. Mitigating cancer disparities in the United States requires intersectoral stakeholder engagement, targeted funding, effective policies at the federal, state, and local levels, and broad implementation of evidence‐based interventions, such as expanding health insurance coverage, including through strengthening Marketplaces and protecting and expanding access to Medicaid.
Thoughts on trends in cancer incidence and mortality and the COVID‐19 pandemic
The United States has built a robust system of registries to assess cancer incidence and mortality. Analysis of cancer registry data can provide insight into what is occurring in cancer control. Registries were critical in understanding the effects of COVID‐19.
Thoughts on trends in cancer incidence and mortality and the COVID‐19 pandemic
The United States has built a robust system of registries to assess cancer incidence and mortality. Analysis of cancer registry data can provide insight into what is occurring in cancer control. Registries were critical in understanding the effects of COVID‐19.
- Open Access
- 2 January 2024
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 84 (1) , 1-2
Franklyn G. Prendergast, MD, PhD: In Memoriam (1945–2023)
On October 12, 2023, Franklyn G. Prendergast, MD, PhD, died of pancreatic cancer. He was a force in science and medicine and a trailblazer in civil rights. He rose from humble beginnings in Jamaica to be a distinguished physician/scientist and a very successful administrator in one of the nation's most distinguished medical centers.Along the way, he became an idol to young minorities and women in medicine and science. His success disproved naysayers who believed Black people did not have the potential to lead. When counseling young minority physicians and scientists, Prendergast would caution that even today there are some who think of themselves as enlightened who have difficulty accepting minorities and women in leadership.Prendergast graduated with honors from the medical school at the University of the West Indies (Jamaica) in 1968. He was then selected as a Rhodes Scholar and attended Lincoln College, University of Oxford. In 1971, he came to the United States to work at Mayo Clinic as an internal medicine resident. In 1977, he earned a PhD in biochemistry from the joint program at the Mayo Graduate School and University of Minnesota. He immediately joined the Mayo Clinic faculty, specializing in protein chemistry. He became a professor of pharmacology, biochemistry, and molecular biology in 1986 and chair of the Department of Biochemistry and Molecular Biology in 1987. He was then named Director for Research for Mayo Clinic in 1989. The following year, he was appointed to the Mayo Board of Governors and the Mayo Foundation. He became the director of the Mayo Clinic Cancer Center in 1995. In 2006, he stepped down as director of the comprehensive cancer center and organized the Mayo Center for Individualized Medicine. He retired from Mayo in 2014.Prendergast also received several honorary doctorates. Among them, from Purdue University and his alma mater, the University of the West Indies. He also received Distinguished Alumni Awards from the University of the West Indies, University of Minnesota, and Mayo Clinic. Prendergast served on the Board of Directors of several companies, among them Eli Lilly, Neubase Therapeutics, Cyclica, Morphimmune, and Medbio. He is especially remembered as a member of the NCI Board of Scientific Advisors and the National Cancer Advisory Board.The National Cancer Institute (NCI) initiated the Cancer Centers Program as a result of President Richard Nixon's National Cancer Act of 1971. Mayo Clinic was one of the first institutions to obtain NCI designation in 1973. By 1995, there were 38 NCI-designated cancer centers. Their directors were and are a prestigious and influential cohort. They have been called “the Senators of American oncology.” Until 1995, all directors of NCI-designated cancer centers were White, and almost all were male. That is when Franklyn Prendergast was named leader of the NCI-designated clinical cancer center at Mayo. In 2000, he took the Mayo Cancer Center from an NCI-designated clinical cancer center to the even more prestigious recognition as an NCI-designated comprehensive cancer center. Thus, Prendergast is not just the first Black person to lead an NCI-designated cancer center, he is the first Black director to take a cancer center to the “comprehensive designation.”As director of the Mayo Clinic Comprehensive Cancer Center, Prendergast was known for mentorship and “managing by walking around.” He would often run into a young scientist in the hallway, stop, and mention that he had been thinking about them and that he had some idea that he wanted to run past them. One now distinguished senior investigator said, “As an early career researcher, this made a huge difference for me to know that the cancer center director remembered my name and took an interest in me.”Indeed, one should not underestimate the importance of men and women like Prendergast who demonstrated what Black people and other minorities could do with competence. His opening of minds and his widespread acceptance created opportunities for others. One prominent Black physician/scientist/administrator who directs an NCI-designated comprehensive cancer center said, “We Black doctors think of Frank as our Jackie Robinson.”Prendergast was a role model who encouraged young men and women of all races/ethnicities to pursue careers in science and medicine at mainstream institutions. Prendergast was a bit of an enigma in Rochester, Minnesota. When asked by a young Black physician about it being unusual for a Jamaican to settle in Rochester, Minnesota, he said, “It's easy once you get used to the fact that they put white cream sauces on everything.” He then laughed and said, “I am talking about more than just food.”In a 2021 graduation speech given at the Mayo Clinic Graduate School of Biomedical Sciences, Prendergast summed up his philosophy of leadership after a life in medicine and decades in one of the nations most distinguished medical institutions. He stressed the importance of mentorship and of creating opportunities for young physicians and scientists. He thanked by name those who were his mentors along the way, freely giving their knowledge, time, and experience. In speaking of his experiences in medicine, he said that one should understand the significance of tradition. “Respect for tradition is one thing, but slavish adherence to tradition quite another. Tradition is vital, but there comes the time when we have to examine the precepts and meaning of a tradition or set of traditions and be willing to change them boldly in the face of new realities.” Going further, he said that one should understand the role of dissent in an institution, emphasizing that “opinions that differ inculcate and engender the habit of critical analysis and review.” He admonished the graduates and faculty to “teach the art of genuinely solicitous and respectful...
- 2 January 2024
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 84 (1) , 1-2
Open AccessFranklyn G. Prendergast, MD, PhD: In Memoriam (1945–2023)
On October 12, 2023, Franklyn G. Prendergast, MD, PhD, died of pancreatic cancer. He was a force in science and medicine and a trailblazer in civil rights. He rose from humble beginnings in Jamaica to be a distinguished physician/scientist and a very successful administrator in one of the nation's most distinguished medical centers.Along the way, he became an idol to young minorities and women in medicine and science. His success disproved naysayers who believed Black people did not have the potential to lead. When counseling young minority physicians and scientists, Prendergast would caution that even today there are some who think of themselves as enlightened who have difficulty accepting minorities and women in leadership.Prendergast graduated with honors from the medical school at the University of the West Indies (Jamaica) in 1968. He was then selected as a Rhodes Scholar and attended Lincoln College, University of Oxford. In 1971, he came to the United States to work at Mayo Clinic as an internal medicine resident. In 1977, he earned a PhD in biochemistry from the joint program at the Mayo Graduate School and University of Minnesota. He immediately joined the Mayo Clinic faculty, specializing in protein chemistry. He became a professor of pharmacology, biochemistry, and molecular biology in 1986 and chair of the Department of Biochemistry and Molecular Biology in 1987. He was then named Director for Research for Mayo Clinic in 1989. The following year, he was appointed to the Mayo Board of Governors and the Mayo Foundation. He became the director of the Mayo Clinic Cancer Center in 1995. In 2006, he stepped down as director of the comprehensive cancer center and organized the Mayo Center for Individualized Medicine. He retired from Mayo in 2014.Prendergast also received several honorary doctorates. Among them, from Purdue University and his alma mater, the University of the West Indies. He also received Distinguished Alumni Awards from the University of the West Indies, University of Minnesota, and Mayo Clinic. Prendergast served on the Board of Directors of several companies, among them Eli Lilly, Neubase Therapeutics, Cyclica, Morphimmune, and Medbio. He is especially remembered as a member of the NCI Board of Scientific Advisors and the National Cancer Advisory Board.The National Cancer Institute (NCI) initiated the Cancer Centers Program as a result of President Richard Nixon's National Cancer Act of 1971. Mayo Clinic was one of the first institutions to obtain NCI designation in 1973. By 1995, there were 38 NCI-designated cancer centers. Their directors were and are a prestigious and influential cohort. They have been called “the Senators of American oncology.” Until 1995, all directors of NCI-designated cancer centers were White, and almost all were male. That is when Franklyn Prendergast was named leader of the NCI-designated clinical cancer center at Mayo. In 2000, he took the Mayo Cancer Center from an NCI-designated clinical cancer center to the even more prestigious recognition as an NCI-designated comprehensive cancer center. Thus, Prendergast is not just the first Black person to lead an NCI-designated cancer center, he is the first Black director to take a cancer center to the “comprehensive designation.”As director of the Mayo Clinic Comprehensive Cancer Center, Prendergast was known for mentorship and “managing by walking around.” He would often run into a young scientist in the hallway, stop, and mention that he had been thinking about them and that he had some idea that he wanted to run past them. One now distinguished senior investigator said, “As an early career researcher, this made a huge difference for me to know that the cancer center director remembered my name and took an interest in me.”Indeed, one should not underestimate the importance of men and women like Prendergast who demonstrated what Black people and other minorities could do with competence. His opening of minds and his widespread acceptance created opportunities for others. One prominent Black physician/scientist/administrator who directs an NCI-designated comprehensive cancer center said, “We Black doctors think of Frank as our Jackie Robinson.”Prendergast was a role model who encouraged young men and women of all races/ethnicities to pursue careers in science and medicine at mainstream institutions. Prendergast was a bit of an enigma in Rochester, Minnesota. When asked by a young Black physician about it being unusual for a Jamaican to settle in Rochester, Minnesota, he said, “It's easy once you get used to the fact that they put white cream sauces on everything.” He then laughed and said, “I am talking about more than just food.”In a 2021 graduation speech given at the Mayo Clinic Graduate School of Biomedical Sciences, Prendergast summed up his philosophy of leadership after a life in medicine and decades in one of the nations most distinguished medical institutions. He stressed the importance of mentorship and of creating opportunities for young physicians and scientists. He thanked by name those who were his mentors along the way, freely giving their knowledge, time, and experience. In speaking of his experiences in medicine, he said that one should understand the significance of tradition. “Respect for tradition is one thing, but slavish adherence to tradition quite another. Tradition is vital, but there comes the time when we have to examine the precepts and meaning of a tradition or set of traditions and be willing to change them boldly in the face of new realities.” Going further, he said that one should understand the role of dissent in an institution, emphasizing that “opinions that differ inculcate and engender the habit of critical analysis and review.” He admonished the graduates and faculty to “teach the art of genuinely solicitous and respectful...
The enigma of race and prostate cancer
Population data support use of race (a sociopolitical demographic) in development of prostate cancer risk profiles and screening algorithms. This is "benevolent racial profiling." We should aspire to develop more scientific and objective precision medicine tools to assess risk of clinically significant prostate cancer, such as germline gene testing and assessment of environmental exposures.
The enigma of race and prostate cancer
Population data support use of race (a sociopolitical demographic) in development of prostate cancer risk profiles and screening algorithms. This is "benevolent racial profiling." We should aspire to develop more scientific and objective precision medicine tools to assess risk of clinically significant prostate cancer, such as germline gene testing and assessment of environmental exposures.
- 1 November 2023
- Published by Wolters Kluwer Health in The Cancer Journal
- Vol. 29 (6) , 287-292
Health Care Policy and Disparities in Health
The United States has seen a 33% decline in age-adjusted cancer mortality since 1991. Despite this achievement, the United States has some of the greatest health disparities of any developed nation. US government policies are increasingly directed toward reducing health disparities and promoting health equity. These policies govern the conduct of research, cancer prevention, access, and payment for care. Although implementation of policies has played a significant role in the successes of cancer control, inconsistent implementation of policy has resulted in divergent outcomes; poorly designed or inadequately implemented policies have hindered progress in reducing cancer death rates and, in certain cases, exacerbated existing disparities. Examining policies affecting cancer control in the United States and realizing their unintended consequences are crucial in addressing cancer inequities.
- 1 November 2023
- Published by Wolters Kluwer Health in The Cancer Journal
- Vol. 29 (6) , 287-292
Health Care Policy and Disparities in Health
The United States has seen a 33% decline in age-adjusted cancer mortality since 1991. Despite this achievement, the United States has some of the greatest health disparities of any developed nation. US government policies are increasingly directed toward reducing health disparities and promoting health equity. These policies govern the conduct of research, cancer prevention, access, and payment for care. Although implementation of policies has played a significant role in the successes of cancer control, inconsistent implementation of policy has resulted in divergent outcomes; poorly designed or inadequately implemented policies have hindered progress in reducing cancer death rates and, in certain cases, exacerbated existing disparities. Examining policies affecting cancer control in the United States and realizing their unintended consequences are crucial in addressing cancer inequities.
- 20 September 2023
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 41 (27) , 4338-4340
On Cancer Screening During the COVID-19 Pandemic
- 20 September 2023
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 41 (27) , 4338-4340
On Cancer Screening During the COVID-19 Pandemic
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Related Article from Oropharyngeal Cancer, Race, and the Human Papillomavirus
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessRelated Article from Oropharyngeal Cancer, Race, and the Human Papillomavirus
- Open Access
- 21 February 2023
- Published by Elsevier in JACC: Cardiooncology
- Vol. 5 (1) , 67-69
The Cause of Death in Patients With Cancer
- 21 February 2023
- Published by Elsevier in JACC: Cardiooncology
- Vol. 5 (1) , 67-69
Open AccessThe Cause of Death in Patients With Cancer